Theralase Technologies Inc (TLTFF)

[123414]

Theralse is exucting a PIVOTAL STUDY... NO-PHASE-THREE REQURIED
The Phase 2 NMIBC trial with 15 treated and 20 to 25 patients needed to
be considered for Breakthrough Therapy Designation is solidly on track.

The company is having great success!

More treatments will be coming soon with 10 hospitals cleared and ready to treat patients.

Further, this is a Pivotal Phase II Non-Muscle Invasive Bladder Cancer study. A Phase 3 study will not be required.

----------------------------


Toronto, Ontario – February 24, 2021,Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (“UWH”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“).